Blood Clot Prevention
After Joint Replacement

Why joint replacement raises clot risk

Venous thromboembolism (VTE) — the umbrella term for deep vein thrombosis (DVT) and pulmonary embolism (PE) — has long been recognised as the most common serious medical complication of hip and knee replacement. The risk comes from a combination of three factors that all converge during this specific type of surgery: reduced blood flow in the leg veins while the patient is immobile on the operating table and during early recovery, direct manipulation and mild injury to blood vessels around the hip or knee during the procedure, and a temporary increase in the blood's clotting tendency as part of the body's normal response to surgical tissue trauma. This combination — first described by the pathologist Rudolf Virchow in the 19th century — is why VTE prevention has become a standard, protocolised part of joint replacement care rather than an afterthought.

Without any preventive treatment, older studies found DVT on routine imaging in a substantial proportion of hip and knee replacement patients, though most of these clots were small, confined to calf veins, and never caused symptoms. The more clinically important number is symptomatic VTE — a clot large enough, or positioned high enough in the leg, to cause noticeable symptoms or travel to the lungs. Modern prophylaxis protocols are built around minimising this symptomatic risk, and have brought reported rates down considerably compared with the pre-prophylaxis era.

How prevention actually works

Modern VTE prevention after joint replacement combines mechanical and pharmacologic (drug-based) measures, and in most protocols, both are used together rather than one or the other.

Mechanical prophylaxis includes early and frequent mobilisation — getting the patient up and walking as soon as it's safe, often the same day or the day after surgery — along with intermittent pneumatic compression (IPC) sleeves or graduated compression stockings, which mechanically squeeze the calf to keep venous blood moving while the patient is resting in bed. Mechanical methods carry no bleeding risk, which makes them useful in patients where blood-thinning drugs are riskier, but they are generally considered a complement to drug prophylaxis rather than a full substitute for it in higher-risk patients.

Pharmacologic prophylaxis is the more actively debated part of the protocol, because every option that reduces clotting also increases bleeding risk to some degree — the entire field is a balancing act between the two. The main agents in current use are compared below.

Agent	How it's given	Key trade-off
Aspirin	Low-dose oral tablet	Simplest, cheapest, no monitoring; evidence on relative effectiveness varies by procedure (see below)
LMWH (e.g. enoxaparin)	Daily subcutaneous injection	Strong trial evidence for reducing symptomatic VTE; requires injections, some bruising/bleeding risk
DOACs (e.g. rivaroxaban, apixaban)	Oral tablet	No injections or routine monitoring; similar efficacy to LMWH in most trials, still a bleeding-risk drug
Warfarin	Oral tablet, dose-adjusted	Long track record but requires regular blood monitoring (INR) to stay in a safe range
Mechanical (IPC/stockings)	Worn continuously post-op	No bleeding risk; used alongside a drug in most protocols, not usually alone in higher-risk patients

What the trial evidence shows

For years, the comparative effectiveness of aspirin versus injectable or oral anticoagulants was debated largely on the basis of smaller trials and registry data. That changed with the CRISTAL trial, one of the largest randomised comparisons in this area to date.

This might sound like a clear result in favour of enoxaparin, but subsequent analyses have added important nuance. A 2025 meta-analysis of randomised trials focused specifically on hip arthroplasty found that aspirin performed comparably to oral anticoagulants for VTE prevention, with no significant difference in DVT/PE rates or bleeding complications — suggesting the picture may differ between hip and knee surgery, and between aspirin-vs-DOAC and aspirin-vs-LMWH comparisons specifically. Other meta-analyses focused on knee replacement have found LMWH modestly outperforming aspirin on VTE rates. Taken together, the evidence base has not settled on one universally superior agent — which is reflected in the guidelines themselves.

The 2024 update to the European guidelines on peri-operative VTE prophylaxis recommends LMWH or a DOAC as first-line pharmacologic prophylaxis after hip or knee replacement, but allows aspirin as an option specifically in "fast-track" (rapid-recovery) surgery pathways with early mobilisation. The American Academy of Orthopaedic Surgeons' clinical practice guideline takes a broader view, listing aspirin, LMWH, warfarin, and factor Xa inhibitors as all acceptable options for patients not at elevated VTE or bleeding risk — reflecting a deliberate choice to let the treating team individualise based on patient factors rather than mandate one drug for everyone.

How long prophylaxis continues

Duration matters as much as the choice of drug. VTE risk after joint replacement doesn't end at hospital discharge — it remains elevated for several weeks while healing and reduced mobility persist. Most protocols continue prophylaxis for a minimum of 10–14 days after surgery, and extended prophylaxis out to around 35 days is common practice after hip replacement in particular, reflecting registry and trial data showing risk persists longer after hip surgery than after knee surgery. The exact duration your own team recommends will depend on the specific procedure, your mobility after surgery, and your individual risk profile.

Personal risk factors that shift the calculus

Some patients carry a materially higher baseline VTE risk, and this is factored into the prophylaxis plan: a personal or family history of DVT/PE, known clotting disorders (thrombophilia), active cancer, obesity, prior major surgery with a clotting complication, immobility beyond the expected recovery course, and use of hormone-based medications (such as certain hormone replacement therapy or oral contraceptives) are all reasons a surgical team might choose a more intensive prophylaxis regimen or extend its duration. Conversely, patients with a personal bleeding disorder, active peptic ulcer disease, or certain liver conditions may need a more cautious approach precisely because the anti-clotting benefit has to be weighed against bleeding risk in the other direction.

Symptoms can develop gradually rather than all at once, so persistent or worsening changes in a leg — even mild ones — are worth reporting to your surgical team rather than assuming they'll resolve on their own. This is especially true in the weeks after discharge, when day-to-day supervision is lighter than it was in hospital.